Literature DB >> 11911725

Q fever during pregnancy: diagnosis, treatment, and follow-up.

Didier Raoult1, Florence Fenollar, Andreas Stein.   

Abstract

BACKGROUND: Q fever, caused by Coxiella burnetii, may result in abortions, premature deliveries, and stillbirths in infected pregnant women.
OBJECTIVE: To evaluate the best treatment strategy for Q fever during pregnancy.
METHODS: We evaluated the prognosis of 17 pregnant women who developed Q fever with and without co-trimoxazole (trimethoprim-sulfamethoxazole) treatment.
RESULTS: The outcome of the pregnancy was found to depend on the trimester. Abortions occurred in 7 of 7 insufficiently treated patients infected during the first trimester vs 1 of 5 patients infected later. Co-trimoxazole given until delivery protected against abortion (0/4) but not against the development of chronic infections, and it did not significantly reduce the colonization of the placenta (2/4 vs 4/4).
CONCLUSIONS: Our results show that C burnetii infections cause abortion and that women who develop Q fever while pregnant should be treated with co-trimoxazole for the duration of pregnancy, specifically when infected during the first trimester.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11911725     DOI: 10.1001/archinte.162.6.701

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  29 in total

1.  Both Major Histocompatibility Complex Class I (MHC-I) and MHC-II Molecules Are Required, while MHC-I Appears To Play a Critical Role in Host Defense against Primary Coxiella burnetii Infection.

Authors:  Laura Buttrum; Lindsey Ledbetter; Rama Cherla; Yan Zhang; William J Mitchell; Guoquan Zhang
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

2.  Survey of laboratory animal technicians in the United States for Coxiella burnetii antibodies and exploration of risk factors for exposure.

Authors:  Ellen A Spotts Whitney; Robert F Massung; Gilbert J Kersh; Kelly A Fitzpatrick; Deborah M Mook; Douglas K Taylor; Michael J Huerkamp; Jessica C Vakili; Patrick J Sullivan; Ruth L Berkelman
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-11       Impact factor: 1.232

Review 3.  Animal models of Q fever (Coxiella burnetii).

Authors:  Kevin R Bewley
Journal:  Comp Med       Date:  2013       Impact factor: 0.982

4.  Introduction to Measurement of Avidity of Anti-Coxiella burnetii IgG in Diagnosis of Q Fever.

Authors:  Léa Luciani; Coralie L'Ollivier; Matthieu Million; Bernard Amphoux; Sophie Edouard; Didier Raoult
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

5.  Coxiella burnetii Avirulent Nine Mile Phase II Induces Caspase-1-Dependent Pyroptosis in Murine Peritoneal B1a B Cells.

Authors:  Laura Schoenlaub; Rama Cherla; Yan Zhang; Guoquan Zhang
Journal:  Infect Immun       Date:  2016-11-18       Impact factor: 3.441

Review 6.  From Q Fever to Coxiella burnetii Infection: a Paradigm Change.

Authors:  Carole Eldin; Cléa Mélenotte; Oleg Mediannikov; Eric Ghigo; Matthieu Million; Sophie Edouard; Jean-Louis Mege; Max Maurin; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 7.  Antimicrobial therapies for Q fever.

Authors:  Gilbert J Kersh
Journal:  Expert Rev Anti Infect Ther       Date:  2013-09-27       Impact factor: 5.091

Review 8.  Infection and stillbirth.

Authors:  Elizabeth M McClure; Robert L Goldenberg
Journal:  Semin Fetal Neonatal Med       Date:  2009-03-12       Impact factor: 3.926

9.  Attenuated Coxiella burnetii phase II causes a febrile response in gamma interferon knockout and Toll-like receptor 2 knockout mice and protects against reinfection.

Authors:  Javier Ochoa-Repáraz; Jami Sentissi; Theresa Trunkle; Carol Riccardi; David W Pascual
Journal:  Infect Immun       Date:  2007-09-24       Impact factor: 3.441

10.  Large Q fever outbreak due to sheep farming near residential areas, Germany, 2005.

Authors:  A Gilsdorf; C Kroh; S Grimm; E Jensen; C Wagner-Wiening; K Alpers
Journal:  Epidemiol Infect       Date:  2007-09-25       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.